ATNM Investor Alert: Class Action Lawsuit Filed Against Actinium Pharmaceuticals, Inc.

NEW YORK, March 30, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a prominent law firm, has announced that a class action lawsuit is currently underway against Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company") as well as some of its executives.

About the Class Action

This lawsuit targets the damages resulting from alleged violations of federal securities laws and is on behalf of all individuals and organizations that purchased Actinium securities from March 31, 2022, to August 2, 2024 (the "Class Period"). Investors who feel they qualify are encouraged to participate in this case by visiting the firm’s website.

Details of the Case

The Complaint claims that throughout the Class Period, the Defendants made significant false and misleading comments. These statements led investors to believe there was a strong chance that the Food and Drug Administration ("FDA") would review and approve Actinium's Biologics License Application ("BLA") for Iomab-B. Specifically, the allegations include: (1) The Defendants consistently highlighted positive data from the Phase 3 Sierra trial, known as the "Sierra Trial", particularly regarding Complete Remission ("DCR"), while minimizing the trial's failure to produce statistically significant or clinically meaningful Overall Survival ("OS") data; and (2) The Defendants allegedly misled investors by suggesting that the FDA had approved the design and methods of the Sierra Trial, indicating that the absence of relevant OS data would not hinder the approval process for the BLA.

Next Steps for Investors

A class action lawsuit is already in motion. If you wish to read a copy of the Complaint or seek more information, you may visit the law firm's website or contact one of their representatives. Investors who experienced financial losses related to Actinium have until May 26, 2025, to apply for the Court to designate them as lead plaintiffs. Note that participating in any recovery does not require one to be designated as lead plaintiff.

No Financial Risk

The firm operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and attorney's fees if they win the case, typically through a percentage of the recovery obtained for the investors.

About Bronstein, Gewirtz & Grossman

Bronstein, Gewirtz & Grossman, LLC is well-regarded nationwide for its work in representing investors in cases of securities fraud and shareholder derivative actions. The firm has successfully recovered hundreds of millions of dollars for investors across the country.

For updates, you can follow the firm on various platforms.

Attorney advertising. Past results do not guarantee similar future outcomes.

Contact Information

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Nathan Miller

332-239-2660

[email protected]

lawsuit, Actinium, investors